This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, K. L.
Right arrow Articles by Naeger, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, K. L.
Right arrow Articles by Naeger, L. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2002, p. 3437-3446, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3437-3446.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

Kirsten L. White,1* Nicolas A. Margot,1 Terri Wrin,2 Christos J. Petropoulos,2 Michael D. Miller,1 and Lisa K. Naeger1

Gilead Sciences, Foster City, California 94404,1 ViroLogic, Inc., South San Francisco, California 940802

Received 8 March 2002/ Returned for modification 14 May 2002/ Accepted 22 July 2002

Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutations K65R and M184V result in changes in susceptibility to several nucleoside and nucleotide RT inhibitors. K65R-containing viruses showed decreases in susceptibility to tenofovir, didanosine (ddI), abacavir, and (-)-ß-D-dioxolane guanosine (DXG; the active metabolite of amdoxovir) but appeared to be fully susceptible to zidovudine and stavudine in vitro. Viruses containing the K65R and M184V mutations showed further decreases in susceptibility to ddI and abacavir but increased susceptibility to tenofovir compared to the susceptibilities of viruses with the K65R mutation. Enzymatic and viral replication analyses were undertaken to elucidate the mechanisms of altered drug susceptibilities and potential fitness defects for the K65R and K65R+M184V mutants. The relative inhibitory capacities (Ki/Km) of the active metabolites of tenofovir, ddI, and DXG were increased for the RT containing the K65R mutation compared to that for the wild-type RT, but the relative inhibitory capacity of abacavir was only minimally increased. For the mutant viruses with the K65R and M184V mutations, the increase in tenofovir susceptibility compared to that of the mutants with K65R correlated with a decrease in the tenofovir inhibitory capacity that was mediated primarily by an increased Km of dATP. The decrease in susceptibility to ddI by mutants with the K65R and M184V mutations correlated with an increase in the inhibitory capacity mediated by an increased Ki. ATP-mediated removal of carbovir as well as small increases in the inhibitory capacity of carbovir appear to contribute to the resistance of mutants with the K65R mutation and the mutants with the K65R and M184V mutations to abacavir. Finally, both the HIV-1 K65R mutant and, more notably, the HIV-1 K65R+M184V double mutant showed reduced replication capacities and reduced RT processivities in vitro, consistent with a potential fitness defect in vivo and the low prevalence of the K65R mutation among isolates from antiretroviral agent-experienced patients.

* Corresponding author. Mailing address: Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404. Phone: (650) 522-5162. Fax: (650) 522-5890. E-mail: kwhite{at}gilead.com.

Antimicrobial Agents and Chemotherapy, November 2002, p. 3437-3446, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3437-3446.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Herrera, C., Cranage, M., McGowan, I., Anton, P., Shattock, R. J. (2009). Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrob. Agents Chemother. 53: 1797-1807 [Abstract] [Full Text]  
  • Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F. (2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother. 52: 4241-4250 [Abstract] [Full Text]  
  • Knoepfel, S. A., Salisch, N. C., Huelsmann, P. M., Rauch, P., Walter, H., Metzner, K. J. (2008). Comparison of G-to-A Mutation Frequencies Induced by APOBEC3 Proteins in H9 Cells and Peripheral Blood Mononuclear Cells in the Context of Impaired Processivities of Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants. J. Virol. 82: 6536-6545 [Abstract] [Full Text]  
  • Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Frangeul, A., Barral, K., Alvarez, K., Canard, B. (2007). In Vitro Suppression of K65R Reverse Transcriptase-Mediated Tenofovir- and Adefovir-5'-Diphosphate Resistance Conferred by the Boranophosphonate Derivatives. Antimicrob. Agents Chemother. 51: 3162-3167 [Abstract] [Full Text]  
  • Perez-Bercoff, D., Wurtzer, S., Compain, S., Benech, H., Clavel, F. (2007). Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages. J. Virol. 81: 4540-4550 [Abstract] [Full Text]  
  • Sluis-Cremer, N., Sheen, C.-W., Zelina, S., Torres, P. S. A., Parikh, U. M., Mellors, J. W. (2007). Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors. Antimicrob. Agents Chemother. 51: 48-53 [Abstract] [Full Text]  
  • Margot, N. A., Waters, J. M., Miller, M. D. (2006). In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine. Antimicrob. Agents Chemother. 50: 4087-4095 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Ray, A. S., Yang, H., Qi, X., Xiong, S., Zhu, Y., Miller, M. D. (2006). Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus.. Antimicrob. Agents Chemother. 50: 2471-2477 [Abstract] [Full Text]  
  • Van Rompay, K. K. A., Singh, R. P., Heneine, W., Johnson, J. A., Montefiori, D. C., Bischofberger, N., Marthas, M. L. (2006). Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.. J. Virol. 80: 6399-6410 [Abstract] [Full Text]  
  • Nitanda, T., Wang, X., Kumamoto, H., Haraguchi, K., Tanaka, H., Cheng, Y.-C., Baba, M. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine In Vitro. Antimicrob. Agents Chemother. 49: 3355-3360 [Abstract] [Full Text]  
  • Delaunay, C., Brun-Vezinet, F., Landman, R., Collin, G., Peytavin, G., Trylesinski, A., Flandre, P., Miller, M., Descamps, D., the Tonus Trial Study Group, (2005). Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021). J. Virol. 79: 9572-9578 [Abstract] [Full Text]  
  • Stratov, I., Dale, C. J., Chea, S., McCluskey, J., Kent, S. J. (2005). Induction of T-Cell Immunity to Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 79: 7728-7737 [Abstract] [Full Text]  
  • Wainberg, M. A., Brenner, B. G., Turner, D. (2005). Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1671-1678 [Full Text]  
  • Weber, J., Chakraborty, B., Weberova, J., Miller, M. D., Quinones-Mateu, M. E. (2005). Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation. J. Clin. Microbiol. 43: 1395-1400 [Abstract] [Full Text]  
  • Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
  • Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., Cheng, A. K., for the 903 Study Group, (2004). Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. JAMA 292: 191-201 [Abstract] [Full Text]  
  • Deval, J., Navarro, J.-M., Selmi, B., Courcambeck, J., Boretto, J., Halfon, P., Garrido-Urbani, S., Sire, J., Canard, B. (2004). A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions. J. Biol. Chem. 279: 25489-25496 [Abstract] [Full Text]  
  • Stone, C., Ait-Khaled, M., Craig, C., Griffin, P., Tisdale, M. (2004). Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine. Antimicrob. Agents Chemother. 48: 1413-1415 [Abstract] [Full Text]  
  • White, K. L., Chen, J. M., Margot, N. A., Wrin, T., Petropoulos, C. J., Naeger, L. K., Swaminathan, S., Miller, M. D. (2004). Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations. Antimicrob. Agents Chemother. 48: 992-1003 [Abstract] [Full Text]  
  • Deval, J., White, K. L., Miller, M. D., Parkin, N. T., Courcambeck, J., Halfon, P., Selmi, B., Boretto, J., Canard, B. (2004). Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations. J. Biol. Chem. 279: 509-516 [Abstract] [Full Text]  
  • Wolf, K., Walter, H., Beerenwinkel, N., Keulen, W., Kaiser, R., Hoffmann, D., Lengauer, T., Selbig, J., Vandamme, A.-M., Korn, K., Schmidt, B. (2003). Tenofovir Resistance and Resensitization. Antimicrob. Agents Chemother. 47: 3478-3484 [Abstract] [Full Text]  
  • Grim, S. A, Romanelli, F. (2003). Tenofovir Disoproxil Fumarate. The Annals of Pharmacotherapy 37: 849-859 [Abstract] [Full Text]  
  • Jeffrey, J. L., Feng, J. Y., Qi, C. C. R., Anderson, K. S., Furman, P. A. (2003). Dioxolane Guanosine 5'-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase: STEADY STATE AND PRE-STEADY STATE KINETIC ANALYSES. J. Biol. Chem. 278: 18971-18979 [Abstract] [Full Text]  
  • McColl, D. J., Miller, M. D. (2003). The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. J Antimicrob Chemother 51: 219-223 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»